Rheumatoid Arthritis Awareness
Vibeke Strand, MD
Strand reports serving as a consultant for Abbvie, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Celltrion, ChemoCentryx, Eli Lilly, Genentech/Roche, Gilead, GSK, Horizon, Inmedix, Janssen, Kiniksa, Merck, Novartis, Pfizer, Priovant, Regeneron, R-Pharma, Samsung, Sandoz, Sanofi, Scipher, Setpoint, SOFUSA and Sepherix.
VIDEO: Practice-changing FDA approvals for RA
Transcript
Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify cperla@healio.com if there are concerns regarding accuracy of the transcription.
Well, I think the short answer is the JAK... They've made a huge difference. And now of course, there's this back and forth concern about whether there's safety and all of the FDA warnings changes our practice but I'm not sure it really has because most of the payers have insisted that our patients have had a biologic before they get a JAK inhibitor.
And the other part of it is even the economics in terms of the cost to the patients and so on, which we don't know enough about usually means that they get a biologic before a JAK inhibitor. But I'm not sure that many of us really think these are a class effect of the JAKs. And that maybe it's more about the design of the study, the size of the sample and the comorbidities that go along with rheumatoid arthritis.
